In a 30-patient trial led by Washington University School of Medicine, researchers used CRISPR to remove CD33 from donor stem cells before transplant. The edited cells engrafted and appeared to shield healthy blood cells from CD33-targeted therapy, addressing a barrier that limits CAR-T against acut